LRE vs. MDC, ROAD, CCT, GEO, PRIM, EME, CCS, PHM, J, and MTH
Should you be buying Lancashire stock or one of its competitors? The main competitors of Lancashire include Mediclinic International (MDC), Roadside Real Estate (ROAD), The Character Group (CCT), Georgian Mining (GEO), Primorus Investments (PRIM), Empyrean Energy (EME), Crossword Cybersecurity (CCS), Phimedix Plc (PHM.L) (PHM), Jacobs Engineering Group (J), and Mithras Investment Trust (MTH). These companies are all part of the "construction" industry.
Lancashire vs. Its Competitors
Lancashire (LON:LRE) and Mediclinic International (LON:MDC) are both construction companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.
63.4% of Lancashire shares are owned by institutional investors. Comparatively, 39.2% of Mediclinic International shares are owned by institutional investors. 4.6% of Lancashire shares are owned by insiders. Comparatively, 48.9% of Mediclinic International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Lancashire has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Mediclinic International has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
In the previous week, Lancashire had 2 more articles in the media than Mediclinic International. MarketBeat recorded 2 mentions for Lancashire and 0 mentions for Mediclinic International. Lancashire's average media sentiment score of 0.67 beat Mediclinic International's score of 0.00 indicating that Lancashire is being referred to more favorably in the media.
Lancashire pays an annual dividend of GBX 0.24 per share and has a dividend yield of 0.0%. Mediclinic International pays an annual dividend of GBX 3 per share. Lancashire pays out 25.9% of its earnings in the form of a dividend. Mediclinic International pays out 1,304.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Lancashire is clearly the better dividend stock, given its higher yield and lower payout ratio.
Lancashire presently has a consensus target price of GBX 690.25, indicating a potential downside of 0.40%. Given Mediclinic International's higher probable upside, analysts clearly believe Mediclinic International is more favorable than Lancashire.
Lancashire has higher earnings, but lower revenue than Mediclinic International. Mediclinic International is trading at a lower price-to-earnings ratio than Lancashire, indicating that it is currently the more affordable of the two stocks.
Lancashire has a net margin of 37.12% compared to Mediclinic International's net margin of 4.99%. Lancashire's return on equity of 10.76% beat Mediclinic International's return on equity.
Summary
Lancashire beats Mediclinic International on 13 of the 17 factors compared between the two stocks.
Get Lancashire News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lancashire Competitors List
Related Companies and Tools
This page (LON:LRE) was last updated on 10/8/2025 by MarketBeat.com Staff
